Stockholders' Equity Attributable to Parent of Universe Pharmaceuticals INC from 30 Sep 2018 to 30 Sep 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
- Summary
-
Universe Pharmaceuticals INC quarterly Stockholders' Equity Attributable to Parent in USD history and change rate from 30 Sep 2018 to 30 Sep 2025.
- Universe Pharmaceuticals INC Stockholders' Equity Attributable to Parent for the quarter ending 30 Sep 2025 was $56,129,510, a 23% increase year-over-year.
- Source SEC data
- View on sec.gov
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)
Universe Pharmaceuticals INC Quarterly Stockholders' Equity Attributable to Parent (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | $56,129,510 | +$10,626,569 | +23% | 30 Sep 2025 | 20-F | 29 Jan 2026 | 2025 | FY |
| Q3 2024 | $45,502,941 | -$27,924,650,059 | 30 Sep 2024 | 20-F | 29 Jan 2026 | 2025 | FY | |
| Q1 2024 | $26,744,096 | -$20,382,575 | -43% | 31 Mar 2024 | 6-K | 20 Sep 2024 | 2024 | Q2 |
| Q3 2023 | $27,970,153,000* | -$7,360,375,000 | 30 Sep 2023 | 20-F | 29 Jan 2026 | 2025 | FY | |
| Q1 2023 | $47,126,671 | -$14,031,611 | -23% | 31 Mar 2023 | 6-K | 20 Sep 2024 | 2024 | Q2 |
| Q3 2022 | $35,330,528,000* | +$35,283,535,691 | 30 Sep 2022 | 20-F | 29 Jan 2026 | 2025 | FY | |
| Q1 2022 | $61,158,282 | +$10,468,021 | +21% | 31 Mar 2022 | 6-K | 31 Aug 2023 | 2023 | Q2 |
| Q3 2021 | $46,992,309 | +$26,189,405 | +126% | 30 Sep 2021 | 20-F | 29 Apr 2025 | 2024 | FY |
| Q1 2021 | $50,690,261 | 31 Mar 2021 | 6-K | 16 Aug 2022 | ||||
| Q3 2020 | $20,802,904 | +$8,418,845 | +68% | 30 Sep 2020 | 20-F | 30 Jan 2024 | 2023 | FY |
| Q3 2019 | $12,384,059 | +$2,702,487 | +28% | 30 Sep 2019 | 20-F | 10 Feb 2023 | 2022 | FY |
| Q3 2018 | $9,681,572 | 30 Sep 2018 | 20-F | 31 Jan 2022 | 2021 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.